AbCellera rakes in Series A funding
Vancouver, British Columbia-based AbCellera, a developer of next-generation therapeutic antibodies, has raised $10 million in Series A financing. DCVC Bio led the round. In conjunction with the fundraising, John Hamer, managing partner at DCVC Bio, has joined AbCellera’s board of directors while Doug Janzen will be stepping down from his role as board chairman.
27 September 2018•1 min read
